短期应用阿托伐他汀联合依折麦布对原发性肾病综合征合并高脂血症患者降脂疗效及相关指标的影响

发布时间：2018-04-23 01:40

本文选题：肾病综合征 + 依折麦布　；参考：《中国药房》2017年06期

【摘要】：目的:探讨短期应用阿托伐他汀联合依折麦布对原发性肾病综合征合并高脂血症患者降脂疗效及相关指标的影响。方法:回顾性收集50例原发性肾病综合征合并高脂血症患者资料,按照用药不同分为联合组和对照组,每组25例。两组患者均采取低盐低脂、优质蛋白饮食,给予泼尼松1 mg/(kg·d),口服,qd,同时配合抗凝、利尿、抗感染治疗,必要时加用细胞毒性药物进行治疗。在此基础上,对照组患者给予阿托伐他汀钙片20 mg,睡前服用,qd;联合组患者给予阿托伐他汀钙片(用法用量同对照组)+依折麦布片10 mg,qd。两组疗程均为2周。观察两组降脂疗效,比较两组患者治疗前后低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、24 h尿蛋白定量(M-TP)、血清白蛋白(Alb)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、血肌酐、尿素氮水平,记录治疗期间不良反应发生情况。结果:两组患者降脂总有效率比较,差异均无统计学意义(P0.05)。治疗后,两组患者LDL-C、TC、HDL-C水平显著低于同组治疗前,ALT水平显著高于同组治疗前,联合组患者Alb显著高于同组治疗前,但组间比较差异均无统计学意义(P0.05)。两组患者治疗前后TG、M-TP、AST、血肌酐、尿素氮水平比较,差异均无统计学意义(P0.05)。结论:阿托伐他汀联合依折麦布可以改善原发性肾病综合征合并高脂血症患者血脂情况,但短期内疗效和安全性与单用阿托伐他汀相当。
[Abstract]:Objective: to investigate the effect of short-term application of Atto vastatin combined with Ezeimebum on lipid lowering in patients with primary nephrotic syndrome and hyperlipidemia. Methods: the data of 50 patients with primary nephrotic syndrome complicated with hyperlipidemia were collected retrospectively and divided into two groups: combined group and control group, 25 cases in each group. The patients in both groups were treated with low salt and low fat, high quality protein diet, prednisone 1 mg/(kg DX, oral administration of QD, anticoagulant, diuretic, antiinfective therapy and, if necessary, cytotoxic drugs. On this basis, the patients in the control group were given 20 mg of Atto vastatin calcium tablets, and the patients in the combined group were given Atto vastatin calcium tablets (with the same dosage as the control group) of 10 mg / g QD. The course of treatment was 2 weeks in both groups. Observe the effect of reducing fat in two groups, To compare low density lipoprotein cholesterol (LDL-C), triacylglycerol (TGN), total cholesterol (TC), HDL-CU (24 h urine protein), serum albumin (Alb), alanine aminotransferase (alt), aspartate aminotransferase (ASTT), serum creatinine (SCR) in the two groups before and after treatment. Urea nitrogen level. Adverse reactions during treatment were recorded. Results: there was no significant difference in the total effective rate of lipid lowering between the two groups (P 0.05). After treatment, the level of LDL-CnTCn HDL-C in the two groups was significantly lower than that in the same group before treatment, and the level of Alb in the combined group was significantly higher than that in the same group before treatment, but there was no significant difference between the two groups (P 0.05). There was no significant difference in serum creatinine and urea nitrogen levels between the two groups before and after treatment (P 0.05). Conclusion: Atto vastatin combined with Ezeimebum can improve blood lipid in patients with primary nephrotic syndrome and hyperlipidemia, but the efficacy and safety in the short term are similar to that of Atto vastatin alone.
【作者单位】：沈阳军区总医院药剂科;沈阳药科大学生命科学与生物制药学院;沈阳军区总医院肾内科;
【分类号】：R692;R589.2

【参考文献】